NasdaqGM - Nasdaq Real Time Price USD

Axsome Therapeutics, Inc. (AXSM)

Compare

90.10

-4.27

(-4.52%)

At close: December 13 at 4:00:02 PM EST

90.00

-0.10

(-0.11%)

After hours: December 13 at 5:19:37 PM EST

Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks yesterday

AXSM
-4.52%
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial. AXS-12 was also well tolerated with long-term dosing, and its safety profile was consistent with that observed in previously completed trials. The primary endpoint was achieved with patients randomized to switch to placebo experiencing a mean increase of 10.29 cataplexy attacks per week compar

Benzinga 16 days ago

AXSM
-4.52%
Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Simply Wall St. 17 days ago

AXSM
-4.52%
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo (p=0.011, NSAQ) Statistically significant improvement in narcolepsy overall compared to placebo (p=0.024, PGI-C) Cataplexy response (≥50% improvement) achieved by 72% of patients at 1 month and 82% at 6 months Improvement in excessive daytime sleepiness (EDS), assessed by the CGI-C, achieved by 84% of

GlobeNewswire 17 days ago

AXSM
-4.52%
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.

Zacks 30 days ago

AXSM
-4.52%
Q3 2024 Axsome Therapeutics Inc Earnings Call

Q3 2024 Axsome Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 30 days ago

AXSM
-4.52%
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

AXSM earnings call for the period ending September 30, 2024.

Motley Fool last month

AXSM
-4.52%
Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains

Investors rally behind Axsome's explosive growth, with FDA approvals and breakthrough drugs driving momentum.

GuruFocus.com last month

AXSM
-4.52%
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth Sunosi® 3Q 2024 net product revenue of $24.4 million representing 21% year-over-year growth Second expansion of Auvelity psychiatry sales force planned for 1Q 2025 NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025 Topline results of ADVANCE-2 an

GlobeNewswire last month

AXSM
-4.52%
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 - Nov. 10, 2024, in Colorado Springs, Colorado. Details for the presentations are as follows: Majo

GlobeNewswire last month

AXSM
-4.52%
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks last month

AXSM
-4.52%
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations from across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024, being held Oct. 29 - Nov. 2, 2024, in Boston, Massachusetts. Details for the presentations are as follows: Major Depressive Disorde

GlobeNewswire last month

AXSM
-4.52%
3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Yes, bargains can still be found in the stock market.

Motley Fool last month

PFE

AXSM
-4.52%
CRSP
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will report its financial results for the third quarter of 2024 on Tuesday, November 12, 2024, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To p

GlobeNewswire last month

AXSM
-4.52%
1 Under-the-Radar Biotech Stock to Buy and Hold

It could be an industry giant in the making.

Motley Fool 2 months ago

AXSM
-4.52%
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

Seven presentations highlight the Company’s growing CNS portfolio and commitment to improving treatment outcomes for patients with sleep disordersNEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations on AXS-12 and solriamfetol at Sleep Europe 2024, the 27th Congress of the European Sleep Research S

GlobeNewswire 2 months ago

AXSM
-4.52%
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.

Zacks 3 months ago

AXSM
-4.52%
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

FDA sets PDUFA action goal date of January 31, 2025NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the Company’s New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. The FDA designated the resubmission as

GlobeNewswire 3 months ago

AXSM
-4.52%
Axsome Therapeutics to Participate in Investor Conferences in September

Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York Wells Fargo Healthcare Conference on September 5 in Boston Baird 2024 Global Healthcare Conference on September 11 in New York Cantor Global Healthcare Conference on September 18 in New York NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will par

GlobeNewswire 3 months ago

AXSM
-4.52%
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today announced that it has reached agreement with Sandoz Inc. (Sandoz) to dismiss the patent litigation related to Axsome’s product Sunosi® (solriamfetol). The litigation, which was pending in the United States District Court for the District of New Jersey, resulted from submission by S

GlobeNewswire 3 months ago

AXSM
-4.52%

Performance Overview

Return	AXSM	S&P 500
YTD	+13.21%	+26.86%
1-Year	+28.42%	+30.31%
3-Year	+171.79%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Axsome Therapeutics, Inc. (AXSM)

Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

Q3 2024 Axsome Therapeutics Inc Earnings Call

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

1 Under-the-Radar Biotech Stock to Buy and Hold

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Axsome Therapeutics to Participate in Investor Conferences in September

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

Performance Overview